Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
TIL
Instil Bio
TIL · NASDAQ · Biological Products, (No Diagnostic Substances)
No open-market purchase by an insider of Instil Bio was filed in the last 90 days. The latest on record was on Mar 23, 2021.
How often do Instil Bio insiders buy and sell shares?
Since 2021, Instil Bio insiders reported 10 open-market purchases and 2 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2021.
Who is selling Instil Bio stock?
No open-market sale by an insider of Instil Bio (TIL) was filed with the SEC in the last 90 days.
Do members of Congress trade TIL?
No trade in Instil Bio (TIL) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−56.3% (−$6.74) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $11.97 on Nov 20, 2025 to $5.23 on Nov 20, 2026 (−56.3%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
$4$8$10$12$14$5.23
DecJan 2026FebMarAprMayJunJulAugSepOctNov
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Dallas, Tx.
Last 12 months
−56.3%
S&P 500 +5.7% over the same dates
Market value
$37.6M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 181K shares sold short (2.5% of shares outstanding), +6.3% vs the previous count, 2.3 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
2 tracked managers disclosed the same change for Q4 2024. From a 13F filed Feb 14, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
4 tracked managers disclosed the same change for Q3 2024. From a 13F filed Nov 14, 2024 covering holdings at Sep 30, 2024 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insider buying and selling since 2021
Insiders of Instil Bio reported 10 open-market purchases and 2 sales since 2021; purchases in 2021.
Year
Bought
Sold
2025
—
$702K2×2 trades
2021
$45M10×10 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Owners above 5%
No Schedule 13D or 13G filing on TIL over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Instil Bio filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 2 open-market sales (about $702K, in 1 filing). (Instil Bio on OQRO)
Contracts, lobbying and filings. FINRA short interest for TIL on the settlement date of Oct 30, 2026 was 181,228 shares (+6.31% on the previous report), about 2.28 days of average volume. In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Jacobs Levy Equity Management, Inc (new position); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Instil Bio filed a Form 8-K on Nov 16, 2026 (Item 2.02) that OQRO classes as: reported its results. Instil Bio filed a Form 8-K on Aug 13, 2026 (Item 2.02) that OQRO classes as: reported its results.
Who holds it. 25 funds reported a stake in Instil Bio in their 13F for Q2 2026. The largest by value: BML Capital Management, LLC (32.2% of the value reported), Vivo Capital, LLC (14.6% of the value reported), Kalehua Capital Management LLC (9.9% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Instil Bio filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 2 open-market sales (about $702K, in 1 filing).
Contracts, lobbying and filings
FINRA short interest for TIL on the settlement date of Oct 30, 2026 was 181,228 shares (+6.31% on the previous report), about 2.28 days of average volume.
In 13F filings for the quarter ended Jun 30, 2026, the largest positions that grew: Jacobs Levy Equity Management, Inc (new position); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press
Instil Bio filed a Form 8-K on Nov 16, 2026 (Item 2.02) that OQRO classes as: reported its results.
Instil Bio filed a Form 8-K on Aug 13, 2026 (Item 2.02) that OQRO classes as: reported its results.
Instil Bio filed a Form 8-K on Apr 3, 2026 (Item 4.01) that OQRO classes as: changed its auditor.
The company's own opening sentence of that report reads: "On April 1, 2026, the Audit Committee of the Board of Directors of Instil Bio, Inc. (the 'Company') approved the appointment of RSM US LLP ('RSM') as the Company’s independent registered public accounting firm for the fiscal year..."
TIL closed at $5.43 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $5.79 to $5.43, a change of −6.2%.
Who holds it
25 funds reported a stake in Instil Bio in their 13F for Q2 2026. The largest by value: BML Capital Management, LLC (32.2% of the value reported), Vivo Capital, LLC (14.6% of the value reported), Kalehua Capital Management LLC (9.9% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 16, 2026.
Latest annual report filed Mar 27, 2026, compared with the one filed Mar 4, 2025. Read the filing
New risk factors in the latest annual report (4 headings)
If Complex Therapeutics LLC is unable to meet the conditions to exercise its option to extend the maturity of its term loan and/or is unable to refinance its term loan or raise sufficient capital to repay its term loan at maturity, or otherwise fails to comply with the terms of the loan agreement, including financial covenants, it could result in an event of default.
If we do not achieve our plans and projected goals in the timeframes we announce, the trading price of our common stock may be negatively impacted.
If our information technology systems or those of the third parties with whom we work or our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.
Non-U.S. holders of our common stock may be subject to U.S. federal income tax if we are considered a United States real property holding corporation.
No longer listed (15 headings from the year before)
We may derive results and data for AXN-2510/IMM2510 and AXN-27M/IMM27M from clinical trials led by ImmuneOnco in China; our role in any such trials and our access to the clinical results and data, will be limited and there is no assurance that the clinical data from any such trials will be accepted or considered by the FDA, or other comparable regulatory authorities.
We may seek Fast Track designation for our product candidates, and we may be unsuccessful. Even if received, Fast Track designation may not actually lead to a faster review or approval process and does not increase the likelihood that our product candidates will receive marketing approval.
We may seek orphan drug designation for some of our product candidates, and we may be unsuccessful, or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity, for product candidates for which we obtain orphan drug designation.
Breakthrough therapy designation by the FDA for any product candidate may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that the product candidate will receive marketing approval.
We plan to work with our collaborator, ImmuneOnco, to conduct clinical trials for AXN-2510/IMM2510 and AXN-27M/IMM27M outside the United States, including China, and the FDA and similar foreign regulatory authorities may not accept data from such trials conducted in locations outside of their jurisdiction.
If we do not achieve our plans and projected development goals in the timeframes we announce and expect, the commercialization of our products may be delayed.
The market opportunities for any current or future product candidate we develop, if approved, may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small.
We may develop AXN-2510/IMM2510, AXN-27M/IMM27M and future product candidates for use in combination with other therapies or third-party product candidates, which exposes us to additional regulatory risks.
And 7 more headings in the filing.
Legal proceedings (Item 3)
From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently subject to any material legal proceedings.
Source: SEC EDGAR, Form 10-K filed Mar 27, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
From “Overview”, in the company's words
We are a biotechnology company focused on identifying and advancing innovative therapeutic opportunities. In January 2026, we announced that our wholly owned subsidiary, Axion Bio, was discontinuing development of AXN-2510, our former lead product candidate. We are actively seeking to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Since inception, we have had significant operating losses. Our net loss was $71.4 million and $74.1 million for the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025, we had an accumulated deficit of $726.5 million.
What the section covers (32 headings)
Overview
Components of Operating Results
Operating Expenses
In-Process Research and Development
Research and Development
General and Administrative
Restructuring and Impairment Charges
Interest Income
Interest Expense
Other Rental Income
Other Income (Expense), Net
Income Tax Provision
Results of Operations
Comparison of the Years Ended December 31, 2025 and 2024
And 18 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 27, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 31.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (15.2% on ATS, 16.0% with other brokers), below its 26-week average of 38.6%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: IBKR ATS (16.6%), POSIT (10.5%), ONECHRONOS (9.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.